European Plavix patent challenge for Sanofi-Aventis
Sanofi-Aventis' blockbuster blood-thinning agent Plavix (clopidogrel), already under patent challenge in the USA from Canada's Apotex and India's Dr Reddy's (Marketletters passim), is now facing similar action, for the first time, in Europe.
The French drug major says it has been notified that its UK patent (issued from its European patent) claiming the active ingredient in Plavix has been challenged by Aircoat Ltd in the Scottish Court. Sanofi-Aventis says it believes that Aircoat's arguments are without merit and will vigorously defend its patent.
A report on this case in the UK's Financial Times says that Aircoat, which seems to be unknown to anyone, is registered at the same address as a law firm. It quotes analysts as saying this could be a move by a generic drugmaker wishing to remain anonymous.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze